|
|
Article: Novavax Board Elects Dr. James B. Tananbaum as Director.
- Article from:
- PR Newswire
- Article date:
- April 28, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Dr. Tananbaum is Co-founder of Prospect Venture Partners II and III, Theravance, Infinity Pharmaceuticals, and GelTex (acquired by Genzyme) -
MALVERN, Pa., April 28 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that its board of directors has elected James B. Tananbaum, M.D., as a director, effective immediately. Dr. Tananbaum is managing director of Prospect Venture Partners, a venture capital firm based in Palo Alto, Calif.
Prospect Venture Partners III recently accumulated a substantial stock equity position in Novavax through a combination of open market purchases and a direct placement from the company.
On behalf of the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Distinguished Venture Capitalist to Speak at the 5th Annual C21 ...
PR Newswire;
April 24, 2003 ;
700+ words
... ... LaPorte, General Partner, Sprout Group Venture Partners and Stuart Collinson, Partner, Forward Ventures ... Inc., Norak Biosciences Inc., Prism Venture Partners, Prospect Venture Partners, Quorex Pharmaceuticals, S.R. One, Limited ...
|
|